Company Overview and News

2
Gemalto NV's (GTOFF) CEO Philippe Vallée on Q1 2018 Results - Earnings Call Transcript

2018-04-29 seekingalpha
Good afternoon and welcome to our 2018 First Quarter Revenue Call. I'm Philippe Vallée the CEO of Gemalto. And today, I'm with Virginie Dupérat-Vergne, our CFO; and Jean-Claude Deturche, our Investor Relations Officer. Together, we will commenting the presentation that you can download from our website. We will begin the key elements of the release, and then we will take your questions. So after having carefully read the information on Page 2 and Page 3, I invite you to go to Page 5 to the highlights of this first quarter.
GTOFF GTO

67
PRESS DIGEST- British Business - April 19

2018-04-19 reuters
April 19 (Reuters) - The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy.
INTU FB DLAR DLUEY CCRGF MSFT GTO DELRF

0
PRESS DIGEST- Financial Times - April 19

2018-04-19 reuters
April 19 (Reuters) - The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy.
DLAR DLUEY GTO DELRF

0
Brexit Bulletin: Brexit Fever - Bloomberg

2018-04-04 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
DLAR DLUEY GTO DELRF

13
UPDATE 1-UK Stocks-Factors to watch on April 3

2018-04-03 reuters
April 3 (Reuters) - Britain’s FTSE 100 index is seen opening 46 points lower at 7,011 on Tuesday, according to financial bookmakers, with futures down 1.15 percent ahead of the cash market open.
ESL MRO HSB DLUEY HSBC.PRA MLSRF HSBC MLSPF HBCYF HCS.PRB FOX CGEN AAL 533264 HCS DELRF VEDL 0005 MLSPY VED DLAR AAUKF HSEA HSEB FOXA NGLOY GTO

8
UK Stocks-Factors to watch on April 3

2018-04-03 reuters
April 3 (Reuters) - Britain’s FTSE 100 index is seen opening 46 points lower at 7,011 on Tuesday, according to financial bookmakers.
ESL MRO HSB DLUEY HSBC.PRA MLSRF HSBC MLSPF HBCYF HCS.PRB CGEN AAL 533264 HCS DELRF VEDL 0005 MLSPY VED DLAR AAUKF HSEA HSEB NGLOY GTO

0
PRESS DIGEST- Financial Times - April 3

2018-04-03 reuters
April 3 (Reuters) - The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy.
DLAR DLUEY SSLZY GTO DELRF

0
British firm De La Rue to challenge government on passport contract -FT

2018-04-02 reuters
(Reuters) - British passport-making company De La Rue Plc is set to challenge the British government’s decision that allows Franco-Dutch company Gemalto NV to make new blue national passports from 2019, the Financial Times reported on Monday.
DLAR DLUEY GTO DELRF

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to EPA:GTO / GEMALTO on message board site Silicon Investor.

WPO: Washington Post Co. Kensington Resources Ltd. (V.KRT) * Diamond in the rough!
Washington Doesnt Get It WM - WASHINGTON MUTUAL
Genitope GTOP Lexington Resources, Inc. (LXRS)
LEGATO SYSTEMS LGTO Remington Oil (REM)
Haddington HDN-ASX Kensington Resources